Ovarian Tumor Biopsies to Study Response to Treatments

Status Completed

Clinical Trial Summary

This is a research study to look at differences in tumor tissue from ovarian cancer patients that may help to determine response and resistance to treatments.

Clinical Trial Description

Ovarian cancer participants will be asked to have two tumor biopsies during the research study. The first biopsy will be done prior to receiving the participants' assigned treatments as a part of their cancer care and the second biopsy will be done about 3-7 days after starting treatment. Participants who will undergo neoadjuvant treatment and then surgery, will also have their tumor tissue collected during surgery. Participants whose disease worsens while on treatment will also be asked to have an additional, optional tumor biopsy. The tumor tissue samples will be studied to look at certain proteins and enzymes, including enzymes called kinomes, that may be important in determining response and resistance to the treatment that participants will receive as a part of their cancer care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02952521
Study type	Observational
Source	University Health Network, Toronto
Contact
Status	Completed
Phase
Start date	January 25, 2017
Completion date	October 28, 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03393884` - Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)	Phase 1/Phase 2
Recruiting	`NCT05200559` - T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04546373` - Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Active, not recruiting	`NCT03371693` - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer	Phase 3
Completed	`NCT01442051` - Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer	N/A
Not yet recruiting	`NCT04983550` - Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC	Phase 2
Completed	`NCT02480374` - Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer	Phase 1
Recruiting	`NCT01680575` - Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer	N/A
Terminated	`NCT01202890` - Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer	Phase 1
Completed	`NCT00561795` - Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors	Phase 2
Completed	`NCT00314678` - Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer	Phase 2
Not yet recruiting	`NCT04889495` - A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Not yet recruiting	`NCT06010667` - A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Recruiting	`NCT06085456` - Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study
Completed	`NCT06366997` - Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
Active, not recruiting	`NCT05212779` - Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Recruiting	`NCT04620954` - Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin	Phase 1/Phase 2
Completed	`NCT02312661` - Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer	Phase 1
Completed	`NCT01666444` - VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Phase 2
Completed	`NCT01891344` - A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)	Phase 2